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Abstract
Background: Endomyocardial Fibrosis (EMF) is a tropical restrictive cardiomyopathy of unknown etiology with high
prevalence in Sub-Saharan Africa, for which it is unclear whether the primary target of injury is the endocardial endothelium,
the subendocardial fibroblast, the coronary microcirculation or the myocyte. In an attempt to explore the possibility of
endocardial lesions being a result of an immune response against the myocyte we assessed the presence and frequency of
circulating anti-myocardial antibodies in EMF patients.
Methodology/Principal Findings: EMF classification, assessment of severity and staging was based on echocardiography.
We used sodium dodecylsulfate polyacrylamide gel electrophoresis (SDS-PAGE) of myocardial proteins followed by western
blotting to screen serum samples for antiheart antibodies G and M classes. The degree of serum reactivity was correlated
with the severity and activity of EMF. We studied 56 EMF patients and 10 healthy controls. IgG reactivity against myocardial
proteins was stronger and more frequent in patients with EMF when compared to controls (30/56; 53.6% vs. 1/10; 10%,
respectively). IgM reactivity was weak in both groups, although higher in EMF patients (11/56; 19.6%) when compared to
controls (n=0). EMF patients showed greater frequency and reactivity of IgG antibodies against myocardial proteins of
molecular weights 35 kD, 42 kD and 70 kD (p values ,0.01, ,0.01 and ,0.05 respectively).
Conclusions: The presence of antibodies against myocardial proteins was demonstrated in a subset of EMF patients.
These immune markers seem to be related with activity and might provide an adjunct tool for diagnosis and
classification of EMF, therefore improving its management by identifying patients who may benefit from
immunosuppressive therapy. Further research is needed to clarify the role of autoimmunity in the pathogenesis of
EMF.
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Introduction
Endomyocardial Fibrosis (EMF) is a tropical cardiomyopathy of
unclear etiopathogenesis and poor prognosis, which is endemic in
certain regions of sub-Saharan Africa [1]. It is probably the
commonest form of restrictive cardiomyopathy, affecting primarily
children and adolescents. The distinctive pathological feature of
established EMF is endocardial thickening of one or both
ventricles, more prominent at the apices and the inflow tracts,
usually causing dysfunction of the atrioventricular valve [1,2].
The diagnosis of EMF is usually made in late stages of the
disease, when heart failure or its complications are already present,
and is based on clinical and echocardiographic features. Although
hypereosinophilia is a common finding in African patients, no
biological marker is currently available for early detection.
Medical management of EMF aims at controlling episodes of
heart failure and its complications, as well as treating hypereosi-
nophilia using oral corticosteroids [2,3]. Surgery is recommended
to symptomatic patients since it increases survival [4] and
improves the quality of life, but has been associated with high
morbidity and mortality [5], and has progressed slowly due to lack
of facilities for open-heart surgery in most regions where the
disease is endemic.
The primary target of injury in EMF is not known. It has
been suggested that the endomyocardial lesions may be the
result of a primary injury to the endocardial endothelium,
subendocardial fibroblast, coronary microcirculation or myo-
cytes [3].
In an attempt to explore the possibility of endocardial lesions
being a result of an autoimmune response against the myocytes
we assessed the presence and frequency of circulating IgM and
IgG class anti-myocardial antibodies in different forms and stages
of the disease.
Methods
Serum was obtained from 56 consecutive EMF patients from
the Mozambican clinical registry and 10 blood donors from the
same population. All controls were submitted to transthoracic
echocardiography to rule out the presence of cardiac disease.
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The National Bioethical Committee for Health from Mozam-
bique approved the study protocol. Written informed consent was
obtained from all patients and controls.
Protocol for clinical evaluation of patients
EMF diagnosis was based on the demonstration of mural and/or
valvar endocardial thickening and other echocardiographic features
of EMF described elsewhere [2]. The disease was defined as right
( R E F M ) ,l e f t( L E M F )a n db i l a t e r a l( B E M F )a c c o r d i n gt ot h e
predominance of structural lesions in one or both sides of the heart.
The severity of endocardial lesions was determined using a
standardized scoring system that defines four different grades,namely
mild (I), moderate (II), severe (III) and advanced (IV) [6]. Finally,
activity was defined based on the presence of clinical sings such as
fever,periorbital edema, urticaria, recrudescence of heart failure, and
laboratory findings of increased erythrosedimentation rate and severe
hypereosinophilia (absolute eosinophil count .1.5610
9/L); in the
absence of any of those clinical sings for more than 6 months patients
were considered to have remission (quiescent disease) [7].
SDS-PAGE and Western blotting
Normal ventricular myocardium was obtained from a donor
heart and immediately frozen in liquid nitrogen. The myocardial
samples were pulverized while still frozen and homogenized in 1%
SDS. A protein assay was carried out using the dye-binding
procedure of Bradford. Samples (25 mg) were solubilised and
denatured by heating at 70uC for 10 minutes in LDS sample buffer
(Invitrogen). The samples were loaded onto 10% tris-bis gels and
run at 60 mA/gel until the tracking dye reached the end of the gel.
Molecular weight markers (Amersham) were concomitantly run on
each gel. The proteins were electrophoretically transferred to
nitrocellulose at 30 V for 1 hour.
Detection of antiheart antibodies
Nitrocellulose strips carrying separated lanes of myocardial
proteins separated by SDS-PAGE were blocked for 1 h with 3%
w/v nonfat dried milk (Marvel) in phosphate buffered saline
containing 0.05% w/v Tween-20 (blocking solution). Strips were
then incubated with patient’s serum, diluted 1:100 in blocking
solution, and agitated for 1 h at room temperature. After thorough
washing in PBS-twin strips were incubated for a further 1 h in
either peroxidase-conjugated rabbit antihuman IgG (Dako) or
IgM (Dako) at a dilution of 1:500 in blocking solution. The strips
were then washed thoroughly in PBS. Protein bands to which
antiheart antibodies had bound were visualized using enhanced
chemiluminescence detection system (ECL, Amersham). Blots
were incubated with the detection reagent for 1 min and then
exposed to Hyperfilm (Amersham) for 1, 2 and 5 minutes. The
films were developed using an automated radiograph developer.
We defined strong reactivity to either IgG or IgM as the
presence of five or more antiheart antibodies of each class.
Author Summary
Endomyocardial Fibrosis is a tropical disease in which the
heart cannot open properly to receive blood due to a scar
that covers its inner layer. It affects mainly children and
adolescents, and has a poor prognosis because the cause
and mechanisms of scarring are unknown. The conven-
tional treatment is frustrating and does not alter the
natural history of the disease. Despite affecting several
million people worldwide there has been little investiga-
tion on the mechanisms of the disease or drug develop-
ment to improve its prognosis. In this study we investigate
the presence of antibodies against the myocardial cells of
African patients with severe and advanced EMF aiming at
uncovering new pathways for the disease. Our results
reveal that EMF patients have anti-myocardial antibodies
in their blood. The reaction of these antibodies with the
heart may be one of the mechanisms involved in the
genesis of the fibrotic lesions. This knowledge may help in
diagnosing the condition and provide alternatives for its
management, using drugs that reduce the impact of the
circulating antibodies in the cardiac tissue. The significance
of these results needs confirmation on studies involving
larger number of subjects due to frequent finding of
antiheart antibodies in African populations with heart
failure of any cause.
Figure 1. Severe right endomyocardial fibrosis. Echocardiography usually reveals partial obliteration of the right ventricle with cavity
reduction, marked thickening of the moderate band, right atrial and tricuspid annulus dilatation, associated severe with tricuspid regurgitation.
Although there is thickening of both leaflets of the atrioventricular valves, no endocardial thickening is seen on the left side of heart.
doi:10.1371/journal.pntd.0000661.g001
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Quantitative data are given as means 6 SD. Fischer exact test
was used to compare the positive results in patients and controls.
Statistical significance was defined as p values ,0.05. T-test and
analysis of variance were used to compare the differences between
groups of patients divided by type, severity and disease activity.
Results
Characterization of patients and controls
The mean age of patients was 18611 years and there were 35
females (62.5%), while the controls had a mean age of 2062y e a r s
and 5 (50%) were females. Forty-five patients (80.3%) were in New
York Heart Association functional classes III/IV and 18 (32.1%) had
atrial fibrillation. Thirty-two patients (57.1%) had BEMF, 20 (35.8%)
had REMF (Figure 1)a n d4( 7 . 1 % )h a dL E M F( Figure 2).
Advanced (grade IV) disease was present in 35 (62.5%) patients.
Severe hypereosinophilia was presented in 12 (21.4%) patients; 8
(14.3%) had active disease. Table 1 presents patient’s characteristics.
Detection of IgG and IgM
Fifty-four (96.4%) patients tested positive for IgG class anti-
myocardial antibodies whilst 33 (58.9%) tested positive for those of
IgM class. A higher frequency of IgG class antibodies was found in
EMF patients when compared with healthy controls. The difference
was statistically significant for proteins of the following molecular
weights: 42 kD (33; 58.9% in patients versus 0 in controls; p=0.0009),
35 kD (32; 57.1% in patients vs 0 in controls; p=0.0009) and 70 kD
(23; 41.1% in patients versus 0 in controls; p=0.011). Patients had
also higher frequencies of antiheart antibodies against proteins of
60 kD (18; 32.1% versus 0) and 90 kD (19; 33.9% versus 0) molecular
weights, although the differences were not statistically significant (p
values of 0.051 and 0.052, respectively). The summary of frequencies
of IgG class anti-myocardial antibodies in patients with EMF and
control subjects is presented in Table 2.
Controls were negative for all IgM class antibodies but the
difference in frequencies between EMF patients and control
subjects was not statistically significant for any protein. The
proteins more frequently detected were 46 kD (17; 30.4% versus
none in controls, p=0.053) and 80 kD (12; 21.4% versus none in
controls, p=0.19). Table 3 shows the frequency of anti-
myocardial antibodies of IgM class in patients with endomyocar-
dial fibrosis and control subjects.
Reactivity according to disease type, activity and severity
The mean number of antibodies was higher for LEMF
(14.069.1), than for BEMF (8.566.0) and REMF (8.464.2), but
only 4 patients with LEMF were positive for anti-myosin
antibodies. No significant difference was found in the mean
number of antibodies in these three groups (p=0.18, ANOVA).
There were 35 patients with severe and advanced EMF; their
mean number of antibodies (965) was not statistically different
from that found in patients with grades I/II (967; p=0.68, t-test).
Table 4 shows the characteristics of the 8 patients with active
disease; 4 had BEMF, 2 REMF and the remaining 2 had LEMF.
The mean number of antibodies detected was greater for patients
Figure 2. Severe left endomyocardial fibrosis. Echocardiography shows thickening of endocardium at the apex of the left ventricle that has a
spherical shape and has reduced longitudinal dimension and thickening of the anterior leaflet of the mitral valve; left atrial dilatation is associated with
both mitral regurgitation and reduced ventricular compliance. Notice the dilatation of the right cavities caused by elevation in pulmonary pressures.
doi:10.1371/journal.pntd.0000661.g002









Severity of EMF Mild 13 (23.2)
Moderate 8 (14.3)
Severe & Advanced 35 (62.5)
Active disease 8 (14.3)
Atrial fibrillation 18 (32.1)
doi:10.1371/journal.pntd.0000661.t001
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disease (7.163.3) with a p value ,0.001.
Discussion
Autoantibodies against myocardial proteins were detected in EMF
patients,suggesting a roleof autoimmunity in a subset of patients with
this cardiomyopathy. These data corroborate previous findings from
Nigeria [8] and India [9,10], and have the advantage of being
obtained using a technique whose results are easier to interpret [11].
They also support the need toevaluate the role of immunosuppressive
therapy in the management of EMF, considering that its current
treatment is deceiving and does not alter natural history.
Better understanding of the significance of antiheart antibodies
in cardiac disease is needed since they have been demonstrated in
patients with and without heart disease in areas of Africa endemic
for EMF [12,13,14], and occur commonly after several types of
cardiac injury such as surgery [15,16] and myocardial disease [17]
suggesting a non-pathogenic role. Although there has been failure
to demonstrate their in vitro and in vivo cytotoxicity [18], a cause-
and-effect relationship between circulating cardiac myosin auto-
antibodies and impairment of myocyte contractility was recently
demonstrated [19]. Moreover, circumstantial evidence implicates
heart-reactive antibodies in forms of heart disease such as
Rheumatic Heart Disease [20,21], cardiomyopathies [22], post-
myocardial infarction (Dressler’s) syndrome, post-pericardiotomy
Table 2. Frequency of IgG antiheart antibodies in patients with endomyocardial fibrosis (EMF) and healthy controls.
Protein EMF Controls
Molecular Weight ______ 56 ______ ______ 10 ______ Fisher Exact Test
(kD) N+ (%) N– N+ (%) N–
25 13 (23.2) 43 1 (10) 9 0.68
30 13 (23.2) 43 0 (0) 10 0.19
35 32 (57.1) 24 0 (0) 10 0.0009
42 33 (58.9) 23 0 (0) 10 0.0009
46 21 (37.5) 35 0 (0) 10 0.024
60 18 (32.1) 38 0 (0) 10 0.051
70 23 (41.1) 33 0 (0) 10 0.011
80 24 (42.9) 32 1 (10) 9 0.076
90 19 (33.9) 37 0 (0) 10 0.052
100 20 (35.7) 36 2 (20) 8 0.48
110 10 (17.9) 46 0 (0) 10 0.34
150 15 (26.8) 41 2 (20) 8 1.00
N+ number testing positive; N- number testing negative; kD kilo Daltons.
doi:10.1371/journal.pntd.0000661.t002
Table 3. Frequency of IgM antiheart antibodies in patients with endomyocardial fibrosis and healthy controls.
Protein EMF Controls
Molecular Weight ______ 56 ______ ______ 10 ______ Fisher Exact Test
(kD) N+ (%) N – N+ (%)* N –
25 6 (10.7) 50 0 10 0.58
35 8 (14.3) 48 0 10 0.34
40 6 (10.7) 50 0 10 0.58
42 9 (16.1) 47 0 10 0.33
44 6 (10.7) 50 0 10 0.58
46 17 (30.4) 39 0 10 0.053
50 11 (19.6) 45 0 10 0.19
60 11 (19.6) 45 0 10 0.19
70 7 (12.5) 49 0 10 0.58
80 12 (21.4) 44 0 10 0.19
90 4 (7.1) 52 0 10 1.00
100 6 (10.7) 50 0 10 0.58
* All percentages are equivalent to zero.
N+ number testing positive; N- number testing negative; kD kilo Daltons.
doi:10.1371/journal.pntd.0000661.t003
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[23], and immunosuppressive therapy decreases the levels of such
antibodies improving the clinical condition.
It has been suggested that antiheart antibodies are a non-
invasive marker of early disease in some forms of cardiomyopathy
[23], binding to specific cardiac tissue later on, hence the
reduction in circulating levels in advanced forms of dilated
cardiomyopathy [22,24]. We could not replicate these findings in
EMF patients as those with advanced disease presented stronger
reactivity and greater number of anti-myosin antibodies.
Antiheart antibodies were predominant in patients with active
disease, defined by the presence of clinical and/or laboratory signs
of inflammation, including hypereosinophilia. Future research
must clarify the role of hypereosinophilia and define the temporal
changes in autoimmune response in earlier phases of EMF to allow
the use of autoantibodies as a diagnostic tool.
There was high frequency of antibodies of molecular weights of
42 kD, 35 kD and 70 kD, corresponding to Actine, Tropomyosin
and Heat Shock Protein-70 (HSP-70), respectively. HSP-70 is an
extracellular stress protein that can function as a potent
immunological adjuvant attenuating the inflammatory disease
via apparent effects on immunoregulatory T cell populations [25].
The presence of antibodies to this protein in 41% of our patients
may indicate that an additional source of injury in EMF might be
the reduction of proteins involved in cytoprotection.
Our results must be interpreted with caution since lesions of the
endocardium, the myocardium and the interstitium occur in EMF
patients. The homogenized piece of myocardium contains not only
myocardial fibers but also elements of the interstitium and blood
vessel wall, indicating that further research is needed aiming at
identification of the exact proteins targeted by these autoantibod-
ies. Most patients had severe heart failure, which usually correlates
to seropositivity to autoantibodies, irrespective of the nature of the
heart condition [13]. The fact that the majority of our patients
were females (62.5%) might have influenced the results since there
is higher prevalence of autoimmune disease in women, for reasons
that are incompletely understood [26]. Another factor that must
be taken into consideration is the possibility of cardiac, skeletal and
smooth muscle sharing some antigenic determinants, in which case
the antibodies would not be entirely organ specific. Since
hypereosinophilia and recrudescence of heart failure were criteria
for definition of heart failure, it cannot be excluded that part of the
hyperreactivity was only a response to these situations. Finally, the
finding of immune markers in only a proportion of EMF patients
suggests that endomyocardial damage is also mediated by
mechanisms other than autoimmunity.
Conclusion
High levels of circulating anti-myosin antibodies are present in a
subset of patients with EMF. Although their role remains unclear,
these autoimmune markers may provide an adjunct tool for the
classification of EMF and improve its management, by identifying
patients who could benefit from immunosuppressive therapy.
Efforts must be made to clarify the role of autoimmunity in the
pathogenesis of EMF.
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